Knee osteoarthritis is the most common degenerative joint disease and a leading cause of chronic pain, mobility limitation, and reduced quality of life in adults and older people. Radiographic staging remains practical in routine care, but structural severity on imaging does not always correspond to pain intensity or functional loss. This clinical mismatch has increased interest in biochemical markers that reflect active tissue damage. ADAMTS-5, a major aggrecanase involved in cartilage matrix degradation, is a biologically plausible candidate marker for evaluating disease activity in knee osteoarthritis. The manuscript presents an analytical cross-sectional study framework with patient selection criteria, symptom assessment tools, radiographic grading, biomarker measurement principles, and statistical methods for correlation and regression analysis. It also discusses expected findings, common confounders, and limitations of biomarker-based interpretation. ADAMTS-5 is best considered a complementary indicator rather than a stand-alone diagnostic test. If confirmed in larger longitudinal cohorts, ADAMTS-5 profiling may improve patient phenotyping, progression risk assessment, and treatment monitoring in knee osteoarthritis.
O'ralova et al. (Wed,) studied this question.